Brief: Intercept Pharmaceuticals Receives FDA Orphan Drug Designation For The Fixed-Dose Combination Of Oca And Bezafibrate For The Treatment Of Primary Biliary Cholangitis

Intercept Pharmaceuticals

16/05/2023 22:27

May 16 (Reuters) - Intercept Pharmaceuticals Inc
 ICPT.O :
    * INTERCEPT PHARMACEUTICALS RECEIVES FDA ORPHAN DRUG
DESIGNATION
FOR THE FIXED-DOSE COMBINATION OF OCA AND BEZAFIBRATE FOR THE
TREATMENT OF PRIMARY BILIARY CHOLANGITIS (PBC)
    * INTERCEPT PHARMACEUTICALS RECEIVES FDA ORPHAN DRUG
DESIGNATION
FOR THE FIXED-DOSE COMBINATION OF OCA AND BEZAFIBRATE FOR THE
TREATMENT OF PRIMARY BILIARY CHOLANGITIS (PBC)
    * INTERCEPT PHARMACEUTICALS INC - COMPANY ON TRACK TO
COMPLETE
PLANNED INTERIM ANALYSES FROM TWO ONGOING PHASE 2 STUDIES OF
OCA-BEZAFIBRATE COMBINATION IN 2023

Source text for Eikon:  ID:nGNX6l6DDx 
Further company coverage:  ICPT.O 

 ((Reutersbriefs@thomsonreuters.com;))